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Abstract
Angiogenic factors are involved in formation of new blood vessels required for placental development and
function; and critical for fetal growth and development. Soluble fms-like tyrosine kinase 1(sFlt-1) is an anti-
angiogenic protein that inhibits formation of new blood vessels resulting in potential pregnancy complications.
The objective of this study was to undertake a systematic review to assess levels of sFlt-1 in early pregnancy and
association with adverse pregnancy outcomes. PubMed and Medline databases and reference lists were searched
up to July 2010. Inclusion criteria were pregnant women, blood sample taken during first trimester and
assessment/reporting of sFlt-1 concentrations and subsequent pregnancy complications. Twelve relevant studies
were identified of 71 to 668 women. No pooling of results was undertaken due to variation in sFlt-1
concentrations (range, 166-6,349 pg/ml amongst controls), samples used (serum, plasma), different summary
statistics (mean, median, odds ratio) and outcome definitions applied. Levels of sFlt-1 were generally higher among
women who developed preeclampsia (11 studies) or gestational hypertension (two studies), but not significantly
different to normotensive women in most studies. There was no consistent pattern in association between sFlt-1
concentrations and fetal growth restriction (4 studies); and levels were non-significantly higher for women with
postpartum bleeding (1 study) and significantly lower for stillbirths (1 study).This review found no clear evidence of
an association between sFlt-1 levels in first trimester and adverse pregnancy outcomes. However, findings were
affected by methodological, biological and testing variations between studies; highlighting the need for consistent
testing of new biomarkers and reporting of outcome measures.
Background
Despite appropriate antenatal care, unforeseen preg-
nancy complications still arise. Adverse pregnancy out-
comes such as preeclampsia, fetal growth restriction and
stillbirth may share the common basis of abnormal pla-
centation [1,2]. Placental development is facilitated by
the coordinated and complex processes of vasculogen-
esis (de novo formation of blood vessels) and angiogen-
esis (formation of new blood vessels from pre-existing
vessels), both prior to implantation and throughout
gestation. Impairment of these processes may result in
restricted blood flow to the fetus, increased maternal
blood pressure and premature delivery [1-3].
Biomarkers of angiogenesis are proposed as potential
predictors of adverse pregnancy outcomes [1-3]. Soluble
fms-like tyrosine kinase (sFlt-1) is an anti-angiogenic
protein and considered to be one of the most promising
serum biomarkers identified to date [4,5]. sFlt-1 inhibits
vascular endothelial growth factor and placental growth
factor signaling, attenuating the formation of new blood
vessels and promoting maturation of those vessels that
have already been created. sFlt-1 has been implicated in
the pathogenesis of preeclampsia when infusion of
recombinant protein into rodents produced many of the
symptoms of this enigmatic disease [6].
Although increases in sFlt-1 concentrations are
expected during the second and third trimester of
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levels of this protein to arrest placental development,
resulting in pregnancy complications [4,5]. In particular,
elevated levels of sFlt-1 have been reported in the sec-
ond and third trimesters among women with pregnan-
cies complicated by preeclampsia compared to women
with normal pregnancies [5,7,8]. Increased sFlt-1 expres-
sion in the maternal circulation during late pregnancy
has also been found to occur among women with
growth restricted fetuses compared to those with nor-
mally grown infants [9,10], and in women with placental
abruption; although results are inconsistent [11,12].
Levels of anti-angiogenic proteins can be detected
soon after conception, and may provide a means of
screening for women at risk for developing these com-
plications [13,14]. Most studies of sFlt-1 concentrations
and pregnancy outcomes have been conducted late in
pregnancy or at birth with timing of the results inade-
quate for use as a predictive screening tool. The poten-
tial advantages of first trimester screening include the
opportunity to incorporate an additional test into exist-
ing, routine antenatal testing and identification of at-risk
pregnancies at gestations when preventive interventions
may be a realistic option. The aim of this study was to
undertake a systematic review of published studies to
determine whether 1
st trimester sFlt-1 concentrations
are associated with adverse pregnancy outcomes.
Methods
Data Sources
We identified relevant studies by searching PubMed and
Medline databases to identify publications up to May
2011, using the terms: ‘Flt-1’ or ‘VEGFR-1’ in conjunc-
tion with one of the following: ‘pregnancy’, ‘adverse
pregnancy outcomes’, ‘pregnancy complications’, ‘still-
birth’, ‘preterm birth’, ‘prematurity’, ‘small for gestational
age’, ‘SGA’, ‘IUGR’,o r‘preeclampsia’. Search limits were
set to exclude non-human studies, research among men,
or articles published in a language other than English.
We also reviewed the reference lists of identified articles
and relevant review articles on the subject to identify
studies that may have been missed in the initial database
search.
Study Selection
The criteria for inclusion in the present systematic
review were any published studies which: i) investigated
the relationship between sFlt-1 concentration in the
blood (serum or plasma) of pregnant women during the
first trimester (mean specim e nc o l l e c t i o np r i o rt o1 4
weeks gestation) and subsequent pregnancy complica-
tions, and ii) provided mean or median measurements
of sFlt-1 concentrations with standard deviations, risk
estimates with 95% confidence intervals, or data
permitting to the calculation of these. Case-reports, let-
ters, and review articles were excluded from the current
investigation. Pregnancy outcomes were pre-specified,
and included: preeclampsia, stillbirth, preterm birth,
small for gestational age (SGA), and intrauterine growth
restriction (IUGR).
Two reviewers independently assessed each study for
inclusion in the review. Data were independently
extracted from each paper by two reviewers onto a stan-
dard data extraction form. Discrepancies were resolved
by consensus. Studies that met the inclusion criteria
were assessed for: location of study, study design, study
population, gestational age at screening, exposure assess-
ment, sample size, and reported effect measure.
Statistical Analysis
We planned to undertake a meta-analysis of continuous
data and apply the mean difference approach for each
outcome where threshold levels of sFLT-1 were reported
[15]. However, we were unable to pool results because
there was significant variation in the selection of study
populations, the quantification of sFlt-1 (evidenced by
large variations in the reported levels), the samples used
(serum or plasma), the choice of summary statistic
(mean, median and OR) and outcome definitions. Thus,
the general findings from the studies are reported and
the percentage difference (positive or negative) in sFLT-
1 levels among women with or without adverse out-
comes was calculated.
Ethics
No ethics approval was required.
Results
The primary search yielded 373 articles; and one addi-
tional paper was identified through PubMed-suggested
related content. After screening the titles and abstracts
of these studies, 29 publications were identified for
further review based on stated inclusion criteria. Ulti-
mately, twelve studies were included in the present ana-
lysis [16-27]. Figure 1 depicts the selection process,
including reasons for the exclusion of identified publica-
tions. Examples of non-relevant outcomes identified
were cancer, chronic lung disease, arthritis, and periph-
eral artery disease. Non-relevant exposures that were
assessed included angiogenic proteins other than sFlt-1
(such as sEng and VEGF), non-relevant markers (such
as IL-8 and IL-6), and lifestyle factors (such as smoking).
The characteristics of the twelve studies included in
the final review are presented in Table 1. Screening was
performed between 4 and 17 weeks gestation with mean
age of gestation at screening ranging between 9 and
13.7 weeks. The majority of studies identified utilized a
case-control study design with some studies nested
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as a part of larger randomized trials or cohort studies.
There were two prospective cohort studies that included
women attending for prenatal care [25,26]. One of these
studies also included women from an obstetric medicine
clinic [26].
The outcomes reported included preeclampsia (11 stu-
dies) [16-18,20-27], SGA or IUGR (four studies)
[18,21,22,24], gestational hypertension (two studies)
[22,26], and one study each evaluated excessive postpar-
tum bleeding [19] and stillbirth [21]. Concentrations of
sFlt-1 were presented either as mean or median concen-
trations, or as odds ratios (OR) for various levels of sFlt-
1 (continuous, quartiles, or deciles). While assessment
of circulating sFlt-1 was performed using an ELISA test-
ing kit (R&D Systems Pty Ltd) according to manufac-
turers’ guidelines, other aspects of testing and specimen
storage varied between studies (Table 2). Analysis was
performed on either serum or EDTA anti-coagulated
plasma. Sample storage temperatures ranged from -20°C
to -80°C, and the intra- and inter-assay coefficients var-
ied between laboratories along with sensitivity levels.
Only three studies reported the dilution used [16,19,23]
and six laboratories conducted duplicate testing
[20,22,24-27]. In addition, only one study explicitly
reported how long the samples were stored for prior to
testing [22], although two others referenced duration of
sample storage in their discussion sections [16,23] and
another specified that none of the samples had pre-
viously been thawed and refrozen [27].
The outcome most often studied in these investiga-
tions was preeclampsia, with standard and consistent
definitions used to define preeclampsia in all studies
[16-18,20-27]. Investigators typically defined
preeclampsia as new onset hypertension (systolic blood
pressure ≥ 140 mm Hg or diastolic blood pressure ≥
90 mm Hg) occurring after 20 weeks gestation, with
concurrent proteinuria (≥ 2+ by dipstick or ≥ 300 mg
in 24 hours). In some cases, preeclampsia was exam-
ined in subgroups based on timing of diagnosis, either
preterm (< 34 or < 37 weeks gestation) [18,23,26,27]
or term (≥ 37 weeks gestation) [18,26].
The results of the ten preeclampsia studies that
reported either mean or median sFlt-1 concentrations
are presented in Table 3 [16-18,20,22-27]. The con-
centrations of sFlt-1 varied greatly between the studies
with levels in controls (normotensive women) ranging
from 166 to 6,349 pg/ml and this did not appear to be
related to the gestational age at testing. Eight studies
assessed any preeclampsia or preeclampsia at term
and reported the mean or median sFlt-1 concentration
during the first trimester. Of these, six studies found
sFlt-1 levels among women with preeclampsia were
5% to 15% higher compared to women with normal
pregnancies [16,17,20,22,24,25]; however, this eleva-
tion was only statistically significant in one study [16].
One study of term preeclampsia reported a statistically
significant lower concentration (by 19%) among term
preeclamptic women [18], while another found non-
significant lower concentrations [26]. The findings
were similarly variable in the three studies that ana-
lyzed preterm preeclampsia (< 37 weeks gestation)
separately [18,23,26]. Two studies [18,23], found that
concentrations of sFlt-1 were significantly lower (by
19% to 27%) during the first trimester among women
diagnosed with preterm preeclampsia [18,23]. However
a third study found significant increases in maternal
sFlt-1 (by up to 40%) among women with preterm
Figure 1 Identification of studies for inclusion in the systematic review.
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cally significant increase in the median sFlt-1 concen-
tration among women with preeclampsia at < 34
weeks or ≥ 34 weeks gestation was reported in the
final study [27].
Two studies also considered gestational hypertension
(i.e. hypertension during pregnancy without proteinuria).
Thadhani et al found similar first trimester sFlt-1 con-
centrations in women with gestational hypertension
compared to normal controls (942 pg/mL vs. 973 pg/mL
Table 1 Characteristics of studies assessing sFlt-1 in first trimester of pregnancy
Reference Location Study
Design
Type of sample
and gestational
age at screening
Participants Outcome(s) s-FLT1
Summary
measure
Akolekar, 2010 United
Kingdom
nested case-
control
Plasma
11-13 weeks
Singleton pregnancies
Exclusions: hypertension but uncertainty about a
diagnosis of preeclampsia (n = 30), preeclampsia
but stored blood not available (n = 57)
Preeclampsia
< 34 weeks
≥ 34 weeks
median
Baumann, 2008 Switzerland case-control Serum
11-14 weeks
Singleton pregnancies
Exclusions: women with history of hypertensive
disorders, immunological diseases, HELLP, or PE <
34 weeks
Preeclampsia mean,
median
Chaiworapongsa,
2005
Chile case-control Plasma
7-16 weeks
Singleton pregnancies. Exclusions: pregnancies with
fetal anomaly or demise, vaginal bleeding, women
with serious medical conditions, chronic
hypertension, asthma requiring medication, or
requiring the use of anti-platelet or non-steroidal
anti-inflammatory drug.
Preeclampsia mean
Erez, 2008 Chile nested case-
control
Plasma
6-15 weeks
Singleton pregnancies. SGA,
Preeclampsia
(preterm and
term)
median,
OR
Eskild, 2008 Norway nested case-
control
Serum
4-12 weeks
Normotensive pregnant women only. Excessive
postpartum
bleeding
mean
Lynch 2010 USA
2005-2008
prospective
cohort
Serum
10-15 weeks
Singleton pregnancies, women presenting for
prenatal care
Exclusions: intrauterine fetal loss, gestational
hypertension
Preeclampsia mean
Noori 2010 United
Kingdom
prospective
cohort
Serum
10-17 weeks
Singleton pregnancies from routine screening (n =
114) and an obstetric medicine clinic (n = 45)
Preeclampsia,
(preterm and
term)
Gestational
hypertension
geometric
mean
Rana S, 2007 USA,
2001-2003
nested case-
control
Serum
11-13 weeks
Singleton pregnancies delivered > 20 weeks
(livebirths) gestation.
Exclusions: women with history of hypertension,
hypertension 6 weeks postpartum, renal disease, or
diabetes.
Preeclampsia, mean
Smith, 2007 Scotland,
1997-99
nested case-
control
Serum
10-14 weeks
Singleton pregnancies.
Exclusions: stillbirths due to congenital anomalies or
rhesus disease.
Preeclampsia
SGA
Preterm
(extreme and
moderate)
Stillbirth
OR
Thadhani R, 2004 USA,
2001-2003
nested case-
control
Serum
8-14 weeks
Singleton pregnancies > 20 weeks gestation.
Exclusions: women with hypertension > 6 weeks
postpartum, history of thyroid, liver, or chronic renal
disease, or chronic hypertension.
Preeclampsia,
Gestational
hypertension
SGA
mean
Vatten LJ, 2007 Norway,
1992-1994
nested case-
control
Serum
4-12 weeks
Singleton pregnancies Preeclampsia
(preterm and
term)
mean, OR
Wathen KA, 2006 Finland,
2001-2002
longitudinal
case-control
Serum
2-15 weeks
Singleton pregnancies among Caucasian women
Exclusions: women with history of hypertension,
diabetes, chronic disease, or smoke > 5 cigarettes/
day.
Preeclampsia
IUGR
median,
OR
All blood testing done using an ELISA testing kit developed by R&D Systems
SGA = small for gestational age; IUGR = intrauterine growth restriction
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nificantly higher mean concentrations among those with
gestational hypertension (2219 pg/mL vs 1729 pg/mL, P
< 0.01) [26].
Four studies investigated maternal sFlt-1 concentra-
tions and IUGR or SGA [18,21,22,24], however, the defi-
nition of the outcome varied between studies. Two
studies defined SGA as a birth weight below the 10
th
percentile for gestational age [18,22], while a third
defined SGA as a birth weight below the 3
rd percentile
for gestational age [21]. Wathen et al. defined IUGR as
birth weight at least 2 standard deviations below the
national average for gestational age [24]. There was no
consistent pattern in the association between sFlt-1 con-
centrations and IUGR in the three studies that examined
this outcome. In two of the studies [22,24], levels of
sFlt-1 among women with growth restricted infants
were slightly higher compared with control women
(1011 pg/mL vs. 973 pg/mL and 486 pg/mL vs. 432 pg/
mL). However, the other study reported lower sFlt-1
concentrations among the SGA group (1616 pg/mL vs
1788 pg/mL) [18].
Two studies examined the dose-response between
sFlt-1 levels and size at birth with conflicting results
[18,21]. Erez et al. treated sFlt-1 as a continuous vari-
able in a polytomous logistic model, adjusted for mater-
nal age, BMI, and nulliparity; and found that compared
to normal pregnancies, there was no association
between increasing levels of sFlt-1 and delivery of an
SGA neonate (OR 1.00; 95%CI 0.99-1.00) [18]. In
Table 2 sFlt-1 testing characteristics
Reference Storage Temperature Dilution Duplicate Testing Intraassay Coefficient Interassay Coefficient Sensitivity
Akolekar, 2010 -80°C yes 15 pg/mL
Baumann, 2008 -30°C 1:3 3.8% 7.0%
Chaiworapongsa, 2005 -70°C 6.9% 4.8% 17.8 pg/mL
Erez, 2008 -70°C 3.9% 1.4% 17.0 pg/mL
Eskild, 2008 -20°C 1:5 17 pg/mL
Lynch, 2010 -80°C yes 9.9%
Noori, 2010 -70°C yes 3.5 pg/mL
Rana S 2007 -80°C yes 3.5% 8.1%
Smith, 2007 10.4% 14.9% 5 pg/mL
Thadhani, 2004 -80°C yes 3.5% 8.1%
Vatten, 2007 -20°C 1:5 17 pg/mL
Wathen, 2006 -80°C yes 5.0% 8.2% 5 ng/L
All blood testing done using ELISA testing kits developed by R&D Systems.
Table 3 Results from studies assessing the association between 1
st trimester sFlt-1 concentrations (pg/mL) and
preeclampsia (PE)
Reference Mean GA Outcome Cases (Preeclampsia) Controls (normotensive) P-value % difference†
n Flt-1 concentration n sFlt-1 concentration
Studies reporting mean concentrations mean, SD/SE mean, SD/SE
Baumann, 2008 12.3 PE (> 34 weeks) 46 1764 (757) 92 1537 (812) 0.04 +13
Chaiworapongsa, 2005 12.3 PE 34 546 (271) 37 464 (260) 0.10 +15
Lynch, 2010 12.3 PE 31 1374 (639) 637 1313 (521) 0.5 +5
Noori, 2010 13.7 PE (< 37 weeks) 10 2414 (622) 128 1729 (85) < 0.01 +40
PE (≥ 37 weeks) 10 1688 (210) 128 1729 (85) 0.19 - 2
Rana S, 2007 11-13* PE 39 3500 (300) 147 3000 (100) 0.14 +14
Thadhani, 2004 10.7 PE 40 1048 (657) 80 973 (490) > 0.05 + 7
Vatten, 2007 9.0 Preterm PE 110 135 276 166 0.01 -19
Studies reporting median concentrations median median
Akolekar 2010 11-13* PE (< 34 weeks) 30 7099 180 6349 NS +12
PE (≥ 34 weeks) 60 6840 180 6349 NS + 8
Erez, 2008 12.2 PE (< 37 weeks) 17 1308 201 1788 0.03 -27
12.2 PE (≥ 37 weeks) 39 1448 201 1788 0.02 -19
Wathen, 2006 13.7 PE 44 481 51 432 > 0.05 +10
*No mean gestational age (GA) provided
† % difference in case mean or median 1
st trimester sFLT-1 compared with the control level
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1, and showed a tendency towards decreasing risk of
SGA as levels of sFlt-1 increased, in both unadjusted
models (OR 0.92; 95%CI 0.88-0.96, P = 0.02) and mod-
els adjusted for maternal age, ethnicity, parity, BMI,
height, smoking status, and hospital of delivery (OR
0.92; 95%CI 0.82-1.00, P = 0.05), suggesting the greatest
risk for SGA was in the lowest decile of sFlt-1 concen-
tration [21].
Of the other pregnancy outcomes assessed, sFlt-1
concentrations during first trimester were slightly, but
not significantly higher for women who experienced a
postpartum hemorrhage compared with those who did
not (230 pg/mL vs. 204 pg/mL, respectively) [19].
While, compared to controls, the risk of stillbirth due
to placental causes was highest in the lowest decile of
sFlt-1 concentration (OR 0.71, 95% CI 0.53-0.91, p <
0.01), with the risk attenuated with increasing levels of
sFlt-1 [21].
Discussion
This systematic review provides no clear evidence for an
association between sFlt-1 levels in the first trimester
and adverse pregnancy outcomes. However, findings of
this review were affected by methodological, biological
and testing variations between studies, which highlight
the need for consistent testing of new biomarkers and
reporting of outcome measures.
The outcome most often investigated in these studies
was preeclampsia; however, these studies do not provide
a consensus as to the nature of the relationship between
sFlt-1 concentrations during the first trimester of preg-
nancy and onset of preeclampsia. Although the majority
of the studies suggest a higher level of sFlt-1 concentra-
tions in women destined to develop preeclampsia at
term, the elevated levels were not significantly different
in most of the studies. Similarly, three studies that did
not report the exact levels of sFlt-1 in first trimester
reported no significant differences between women with
and without preeclampsia [23,28-30]. This is consistent
with the conclusions of Levine who found that levels
didn’t increase until approximately five weeks before the
onset of clinical disease [5]. In contrast, preterm pree-
clampsia tended to be associated with lower sFlt-1 levels
in first trimester. Despite these differences, one of the
strengths of the preeclampsia studies was the consis-
tency with which preeclampsia was defined and there-
fore differences in outcome assessment do not explain
the dissimilarity of the results obtained. On the other
hand, the studies were small and it is unclear whether
the populations themselves are comparable. Although
some studies stated that women with a history of hyper-
tensive disorders and renal disease were excluded
[16,17,20,22,24], others did not [18,23]. This may be
significant as findings from the two studies that did not
exclude women with previous hypertension [18,23] were
in opposition to those that did [16,17,20,22,24]. The dis-
tribution of other predictors of preeclampsia such as
parity, obesity, smoking and ethnicity [31], was reported
in only few studies.
Similarly no conclusions could be drawn from the stu-
dies that examined the association between first trime-
ster sFlt-1 levels and fetal growth restriction. These
studies were complicated by a lack of consistency in the
outcome definition and variation in testing procedures
and reporting of sFlt-1 concentrations.
A number of factors, including methodological, biolo-
gical and testing differences may have contributed to
the variation in sFlt-1 concentrations observed in the
studies included in our review. Variation in study loca-
tion, characteristics of women, sample size and timing
of serum screening may also impact on sFlt-1 measure-
ments. Furthermore, the large variation in sFlt-1 levels
in the control groups from the included studies also
precludes comparisons. Reporting could be standardized
by presenting the sFlt-1 values as multiples of the med-
ian (MoM), rather than raw concentrations, as is stan-
dard practice in Down syndrome screening [32]. This
would help account for variation between maternal
characteristics, gestational age, settings and testing tech-
niques, and MoM percentile cutoffs would allow for dif-
ferentiation between groups. However, only one study
included in our review recognized and employed this
method [21].
Given that there are no established normative levels of
sFlt-1 in pregnancy, it is difficult to assess how mean-
ingful these differences are, or to define ‘abnormal” ver-
sus ‘normal’ concentrations. Further, there is little
information about the effect of maternal factors such as
smoking and body mass index on sFlt-1 levels. Small
studies have reported changes in sFlt-1 concentrations
between first and second trimester [18] and non-signifi-
cant differences between normal pregnancies and those
affected with preeclampsia [20]. However, large, pro-
spective studies in unselected, ethnically and geographi-
cally diverse pregnant populations with serial,
longitudinal measurements of sFlt-1 levels throughout
pregnancy are required to assess and define the natural
progression of sFlt-1 levels in pregnancy.
The variation in sFlt-1 concentrations also under-
scores the need to understand and ensure results are
comparable between different types of biological sam-
ples. Measurement of serum and plasma may not yield
similar results. With plasma, the choice of anticoagulant
can influence the results; for example EDTA chelates
calcium and impedes the binding of samples in testing
kits which targets a calcium dependent epitope. With
serum, angiogenic factors released from platelets could
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turers’ package reports mean sFlt-1 concentration of 80
pg/ml (range 55-123) and 114 pg/ml (range 75-179) for
EDTA-plasma and serum, respectively (n = 35 samples).
If plasma samples give systematically lower concentra-
tions than serum samples, then comparison between the
two measures may not be reasonable.
Consistent testing practices across settings are also
important to ensure comparability of findings. Technical
differences in the storage and testing of samples may
contribute to increased variability and unreliability of
sFlt-1 measurements. The studies in this review varied
in the length, method and temperature of sample sto-
rage, thawing of samples, duplicate testing; sensitivity of
detection limits, and inter- and intra-assay coefficients
of variation. Of particular importance may be tempera-
ture and length of storage, where samples stored for
long periods at temperatures above -80 degrees may
promote some degradation of proteins [22]. From the
three studies that reported storage duration, these ran-
ged from less than 2 years [16,22] to more than 10 years
[23]. Another factor that may have contributed to the
inter-study variation in the findings is the number of
freeze-thaw cycles samples were exposed to. Only one
study specifically stated that tested samples were only
thawed once [22], and since others made no such
claims, it is difficult to draw any conclusions regarding
the uniformity of the measures.
The large-scale usefulness of predictive biomarkers
remains unclear and such research is rarely presented in
a manner that allows translation to a population level.
For example, a recent study suggesting that pregnancy
associated plasma protein-A (PAPP-A), an antenatal
maternal serum biomarker, could be used as an early
marker for pregnancies at-risk of preeclampsia reported
an odds ratio of 6.6 (95% CI 2.2, 16.9), and concluded
that decreased first trimester PAPP-A is a predictor of
adverse pregnancy outcome [33]. However, extrapolating
results from this paper suggests the marker would per-
form poorly at a population level, such that if 100,000
pregnancies were screened, approximately 5,000 women
would be found to have abnormal PAPP-A levels, but of
those, only 450 would develop preeclampsia compared
to 1,425 among those with normal PAPP-A levels.
Therefore, it is important to establish both the positive
and negative predictive values of sFlt-1 screening before
recommending its use beyond a research setting.
Conclusions
Ideally, identification of high risk women early in preg-
nancy would allow for early interventions to be under-
taken in hopes of reducing incidence of these
outcomes. In the absence of effective interventions, a
biomarker predictor of high risk patients could be
used to identify women for enrolment in intervention
or surveillance trials. The first trimester provides an
opportunity to incorporate sFlt-1 testing into other
routine testing done at the time. Screening during the
2
nd or 3
rd trimester may be too late for preventive
interventions. The studies presented in this paper do
not support a consensus regarding the efficacy of sFlt-
1 as a predictive tool for adverse birth outcomes. How-
ever, other biomarkers used alone or in combination
with sFlt-1 may be more discriminating. This review
underscores the need for uniform testing and reporting
to establish the utility of sFlt-1 as a first trimester
screening instrument.
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